PRCM
SRPT icon

Pine River Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Pine River Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-15,000
Closed -$482K – 734
2015
Q3 		$482K Buy
+15,000
New +$509K 0.01% 549

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Pine River Capital Management's SRPT Position: Q4 2015 in Review

Pine River Capital Management sold out of Sarepta Therapeutics (SRPT) in Q4 2015, closing a stake of 15,000 shares — an estimated $482K sold.

Pine River Capital Management first reported a position in SRPT in Q3 2015 and held it in 1 quarter. The position peaked at $482K in Q3 2015. 151 funds tracked by Wall St. Rank hold SRPT as of Q4 2015.

  • Pine River Capital Management reported no remaining Sarepta Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Pine River Capital Management sold 15,000 Sarepta Therapeutics shares in Q4 2015, an estimated $482K.
  • Pine River Capital Management first reported a position in Sarepta Therapeutics in Q3 2015 and held it in 1 quarter.
  • Pine River Capital Management's Sarepta Therapeutics position peaked at $482K in Q3 2015.
  • 151 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2015.

Based on Pine River Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.